{"user_id":"c635000d-4b10-11ee-a964-aac5a93f6ac1","page":"35-45","department":[{"_id":"JoDa"}],"file_date_updated":"2023-02-02T13:01:20Z","language":[{"iso":"eng"}],"author":[{"last_name":"Glajzer","first_name":"Jacek","full_name":"Glajzer, Jacek"},{"full_name":"Castillo-Tong, Dan Cacsire","first_name":"Dan Cacsire","last_name":"Castillo-Tong"},{"first_name":"Rolf","full_name":"Richter, Rolf","last_name":"Richter"},{"last_name":"Vergote","full_name":"Vergote, Ignace","first_name":"Ignace"},{"last_name":"Kulbe","first_name":"Hagen","full_name":"Kulbe, Hagen"},{"first_name":"Adriaan","full_name":"Vanderstichele, Adriaan","last_name":"Vanderstichele"},{"first_name":"Ilary","full_name":"Ruscito, Ilary","last_name":"Ruscito"},{"last_name":"Trillsch","first_name":"Fabian","full_name":"Trillsch, Fabian"},{"last_name":"Mustea","first_name":"Alexander","full_name":"Mustea, Alexander"},{"id":"382077BA-F248-11E8-B48F-1D18A9856A87","last_name":"Kreuzinger","first_name":"Caroline","full_name":"Kreuzinger, Caroline"},{"first_name":"Charlie","full_name":"Gourley, Charlie","last_name":"Gourley"},{"full_name":"Gabra, Hani","first_name":"Hani","last_name":"Gabra"},{"last_name":"Taube","full_name":"Taube, Eliane T.","first_name":"Eliane T."},{"full_name":"Dorigo, Oliver","first_name":"Oliver","last_name":"Dorigo"},{"first_name":"David","full_name":"Horst, David","last_name":"Horst"},{"full_name":"Keunecke, Carlotta","first_name":"Carlotta","last_name":"Keunecke"},{"last_name":"Baum","full_name":"Baum, Joanna","first_name":"Joanna"},{"last_name":"Angelotti","full_name":"Angelotti, Timothy","first_name":"Timothy"},{"first_name":"Jalid","full_name":"Sehouli, Jalid","last_name":"Sehouli"},{"last_name":"Braicu","full_name":"Braicu, Elena Ioana","first_name":"Elena Ioana"}],"year":"2023","file":[{"date_created":"2023-02-02T13:01:20Z","file_name":"2023_AnnalsSurgicalOncology_Glajzer.pdf","file_size":365865,"date_updated":"2023-02-02T13:01:20Z","content_type":"application/pdf","relation":"main_file","access_level":"open_access","success":1,"file_id":"12490","creator":"dernst","checksum":"36a1200e1011f4b2155a8041d0308f34"}],"ddc":["610"],"article_processing_charge":"No","date_published":"2023-01-01T00:00:00Z","publication":"Annals of Surgical Oncology","date_created":"2023-01-16T09:44:36Z","keyword":["Oncology","Surgery"],"oa_version":"Published Version","type":"journal_article","citation":{"mla":"Glajzer, Jacek, et al. “Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.” <i>Annals of Surgical Oncology</i>, vol. 30, Springer Nature, 2023, pp. 35–45, doi:<a href=\"https://doi.org/10.1245/s10434-022-12459-3\">10.1245/s10434-022-12459-3</a>.","ieee":"J. Glajzer <i>et al.</i>, “Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium,” <i>Annals of Surgical Oncology</i>, vol. 30. Springer Nature, pp. 35–45, 2023.","chicago":"Glajzer, Jacek, Dan Cacsire Castillo-Tong, Rolf Richter, Ignace Vergote, Hagen Kulbe, Adriaan Vanderstichele, Ilary Ruscito, et al. “Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.” <i>Annals of Surgical Oncology</i>. Springer Nature, 2023. <a href=\"https://doi.org/10.1245/s10434-022-12459-3\">https://doi.org/10.1245/s10434-022-12459-3</a>.","ama":"Glajzer J, Castillo-Tong DC, Richter R, et al. Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium. <i>Annals of Surgical Oncology</i>. 2023;30:35-45. doi:<a href=\"https://doi.org/10.1245/s10434-022-12459-3\">10.1245/s10434-022-12459-3</a>","ista":"Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI. 2023. Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium. Annals of Surgical Oncology. 30, 35–45.","apa":"Glajzer, J., Castillo-Tong, D. C., Richter, R., Vergote, I., Kulbe, H., Vanderstichele, A., … Braicu, E. I. (2023). Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium. <i>Annals of Surgical Oncology</i>. Springer Nature. <a href=\"https://doi.org/10.1245/s10434-022-12459-3\">https://doi.org/10.1245/s10434-022-12459-3</a>","short":"J. Glajzer, D.C. Castillo-Tong, R. Richter, I. Vergote, H. Kulbe, A. Vanderstichele, I. Ruscito, F. Trillsch, A. Mustea, C. Kreuzinger, C. Gourley, H. Gabra, E.T. Taube, O. Dorigo, D. Horst, C. Keunecke, J. Baum, T. Angelotti, J. Sehouli, E.I. Braicu, Annals of Surgical Oncology 30 (2023) 35–45."},"_id":"12205","doi":"10.1245/s10434-022-12459-3","publication_identifier":{"eissn":["1534-4681"],"issn":["1068-9265"]},"title":"Impact of BRCA mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: A multicenter retrospective study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) consortium","month":"01","publication_status":"published","publisher":"Springer Nature","scopus_import":"1","oa":1,"related_material":{"record":[{"relation":"other","status":"public","id":"12115"}]},"acknowledgement":"E.I.B. is a Feodor Lynen fellow of the Humboldt Foundation and a participant of the Charité Clinical Scientist Program funded by the Charité Universitätsmedizin Berlin and the Berlin Institute of Health. This work was supported by European Commission’s Seventh Framework Programme under grant agreement no. 279113 (OCTIPS; www.octips.eu).\r\nOpen Access funding enabled and organized by Projekt DEAL.","day":"01","quality_controlled":"1","intvolume":"        30","date_updated":"2023-09-05T15:18:37Z","tmp":{"name":"Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)","short":"CC BY (4.0)","legal_code_url":"https://creativecommons.org/licenses/by/4.0/legalcode","image":"/images/cc_by.png"},"abstract":[{"lang":"eng","text":"Background: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC).\r\n\r\nPatients and Methods: Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups.\r\n\r\nResults: Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence.\r\n\r\nConclusions: Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC."}],"status":"public","article_type":"original","has_accepted_license":"1","external_id":{"isi":["000852125500006"]},"volume":30,"isi":1}